Future of nonnucleoside reverse transcriptase inhibitors

Affiliations

Comment

Nicolas Sluis-Cremer. Proc Natl Acad Sci U S A. 2018.

. 2018 Jan 23;115(4):637-638.

doi: 10.1073/pnas.1720975115. Epub 2018 Jan 11.

¹ Department of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, PA 15261 nps2@pitt.edu.

No abstract available

Conflict of interest statement

The author declares no conflict of interest.

From in silico hit to long-acting late-stage preclinical candidate to combat HIV-1 infection.
Kudalkar SN, Beloor J, Quijano E, Spasov KA, Lee WG, Cisneros JA, Saltzman WM, Kumar P, Jorgensen WL, Anderson KS. Kudalkar SN, et al. Proc Natl Acad Sci U S A. 2018 Jan 23;115(4):E802-E811. doi: 10.1073/pnas.1717932115. Epub 2017 Dec 26. Proc Natl Acad Sci U S A. 2018. PMID: 29279368 Free PMC article.

1. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science. 1992;256:1783–1790. - PubMed
1. Guay LA, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet. 1999;354:795–802. - PubMed
1. Nel A, et al. Ring Study Team Safety and efficacy of a dapivirine vaginal ring for HIV prevention in women. N Engl J Med. 2016;375:2133–2143. - PubMed
1. Baeten JM, et al. MTN-020–ASPIRE Study Team Use of a vaginal ring containing dapivirine for HIV-1 prevention in women. N Engl J Med. 2016;375:2121–2132. - PMC - PubMed
1. Jackson A, McGowan I. Long-acting rilpivirine for HIV prevention. Curr Opin HIV AIDS. 2015;10:253–257. - PubMed